Last updated on December 2017

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD Study

Brief description of study

To assess the single dose PK of galcanezumab administered via subcutaneous injection in a population of pediatric patients aged 6 to 17 years with migraine

Clinical Study Identifier: TX155191

Find a site near you

Start Over

Northwest Clinical Research Center

1951 152nd Pl NE Suite 200 Bellevue, WA USA
  Connect »